“⌚베스트토토안전【평생베스트.com】베스트토토메이저⌚”的搜索结果，显示 111-120 项，共有 6579 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

4. 疼痛医学- 临床试验- 妙佑医疗国际

   The purpose of this study is to evaluate the hormonal profile related to opioid-induced hypogonadism (OIH) in chronic pain patients before and after ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma. Needle-based Confocal Laser Endomicroscopy Guided ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. A Study to Develop ...